Leishmaniasis is a parasitic disease that presents four main clinical syndromes: cutaneous
leishmaniasis (CL), mucocutaneous leishmaniasis (MCL), visceral leishmaniasis/kala azar …

Diagnosis of leishmaniasis has always been a major challenge as its clinical features
resemble some other commonly occurring diseases such as tuberculosis, typhoid, and …

Visceral Leishmaniasis (VL) is the most fatal form of disease leishmaniasis. To date, there
are no effective prophylactic measures and therapeutics available against VL. Recently, new …

Diagnostic parameters for visceral leishmaniasis (VL), a potentially fatal parasitic disease
caused by Leishmania donovani, have been redefined in the last decade with the …

The leishmaniases are protozoan infections that are among the neglected tropical diseases
(NTDs). Over one billion people are at risk of these diseases in virtually all continents. These …

Visceral leishmaniasis (VL) is caused by various species of the genus Leishmania.
Internalization of Leishmania into host cells is facilitated by a large number of receptors, and …

Visceral leishmaniasis (VL) is the most devastating parasitic infection worldwide causing
high morbidity and mortality. Clinical presentation of VL ranges from asymptomatic or …

Background In the current context of high fatality rates associated with American visceral
leishmaniasis (VL), the appropriate use of prognostic factors to identify patients at higher risk …

Parasitic infections are a major global health issue causing significant mortality and
morbidity. Despite substantial advances in the diagnostics and treatment of these diseases …

For decades antimonials were the drugs of choice for the treatment of visceral leishmaniasis
(VL), but the recent emergence of resistance has made them redundant as first-line therapy …